Use of ctDNA for Monitoring of Stage III Colorectal Cancer

Status Active, not recruiting

Clinical Trial Summary

This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

Clinical Trial Description

Circulating tumor DNA (ctDNA) are small fragments of nucleic acid that originate from apoptotic or necrotic tumor cell turnover. Characteristic of the malignant process, ctDNA can be assessed in plasma and offers the potential of a sensitive and specific biomarker for prognostic information on disease-free or overall survival, and predictive information on chemotherapy resistance and probability of lack of response to treatment. This study will evaluate ctDNA as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC). We will recruit newly diagnosed stage III CRC patients, determine their tumor mutational profile, and systematically collect high volume (>10 ml), serial plasma specimens every 3 months for up to 3 years and every 6 months in years 4-5 for ctDNA and concurrent carcinoembryonic antigen (CEA) measurement. Clinical outcome and survival will be tracked. The resulting data will permit assessment of ctDNA as a prognostic marker for disease-free and overall survival and as a monitor of disease recurrence in comparison with CEA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02842203
Study type	Observational
Source	University of Pittsburgh
Contact
Status	Active, not recruiting
Phase
Start date	September 2016
Completion date	September 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04589468` - Researching the Effect of Exercise on Cancer	N/A
Recruiting	`NCT02135887` - A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
Recruiting	`NCT05161585` - Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study	N/A
Not yet recruiting	`NCT04624555` - The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
Not yet recruiting	`NCT06307548` - Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT03095781` - Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	Phase 1
Recruiting	`NCT05954078` - Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer	Phase 3
Active, not recruiting	`NCT04007770` - Acupuncture Pilot Study for Cancer-related Cognitive Function	Phase 2
Recruiting	`NCT03368963` - TAS102 in Combination With NAL-IRI in Advanced GI Cancers	Phase 1/Phase 2
Recruiting	`NCT05631574` - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer	Phase 1
Completed	`NCT03112668` - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners	N/A
Not yet recruiting	`NCT03127111` - Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer
Terminated	`NCT04044430` - Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer	Phase 1
Not yet recruiting	`NCT04513431` - A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)	Early Phase 1
Completed	`NCT05025748` - Ask Questions (ASQ):Implementation of a Communication Intervention	N/A
Recruiting	`NCT05086614` - Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer	Phase 3